| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | CD252, OX40 Ligand, gp34 |
| Conjugate | |
| Formulation | |
| Host | |
| Product Type | |
| Shipping | |
| Storage |
Scientific Background
Human CD252 (CD134L, OX-40 Ligand) is a type II membrane protein with homology to TNF which is expressed on activated B cells and activated endothelial cells. CD252 binds to CD134 present on activated T cells, providing a costimulatory signal (1). This pathway seems to be more effective for costimulation of CD4+ helper T cells than for CD8+ effector T cells (4). Blockade of this interaction in mouse abrogated immunological effects in several models of immflamation and rejection (5,6,7,8). CD252-muCD8 fusion protein binds to CD134 positive cells in Flow cytometry.
Product Description
CHO CellsRecombinant hCD252(OX40L)-muCD8 is a recombinant human fusion protein produced in CHO Cells cells. Molecular Structure: A soluble molecule consisting of the extracellular domain (167aa) of murine CD8 alpha fused to 132 (c-term) amino acids of the extracellular domain of human CD252, with a predicted (non glycosylated) monomeric weight of 34.1 kd. Extracellular mature murine CD8alpha: (28)KPQAPEL….GLDFACD(194); Linking amino acids: TR; extracellular human CD252: (52)VSHRYPR….NPGEFCVL(183).
Alternative names: CD252, OX40 Ligand, gp34
Protein Specifications
| Fusion Format | Murine CD8α Fusion (muCD8) |
|---|---|
| Expression System | CHO Cells |
| Molecular Weight | 34.1 kDa |
| Formulation | 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5% Gentamicin sulfate |
| Storage | Store at 2 - 5°C. Freeze/Thawing is not recommended. |
| Species Reactivity | Human |
| Validated Applications | ELISA, Flow Cytometry |
| Available Conjugates | Biotin, Unconjugated |
✔ Research Use Only (RUO)
Functional Activity
CD134L-muCD8 fusion protein binds to CD134 positive cells in Flow cytometry.
Safety & Handling
Research Use Only. Not intended for diagnostic, therapeutic, or clinical use. Handle according to good laboratory practice (GLP). Consult the Safety Data Sheet (SDS) prior to use.
Related Products
Browse our full collection of recombinant proteins and antibodies for immunology and immune checkpoint research.
This protein was expressed in CHO Cells cells. Mammalian expression is critical for this Fc fusion protein because it ensures proper glycosylation and tertiary folding of the extracellular immunoglobulin-like domains, preserving native receptor-binding activity.
Recombinant hCD252(OX40L)-muCD8 has been validated for: ELISA, Flow Cytometry. It is produced as a Murine CD8α Fusion (muCD8), making it suitable as a blocking reagent, binding standard, or functional stimulant/inhibitor in immunology assays.
Recommended storage: Store at 2 - 5°C. Freeze/Thawing is not recommended.. Formulation: 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5% Gentamicin sulfate. Avoid repeated freeze-thaw cycles. If long-term storage is needed, aliquot upon first use.
Species reactivity includes: human. Cross-reactivity was confirmed by functional binding assays (e.g., ELISA and/or FACS) against cells or recombinant proteins from the indicated species.
Available formats include: Biotin, Unconjugated. Conjugated forms are ready-to-use without secondary detection reagents for flow cytometry. Unconjugated (purified) forms can be used with anti-Fc secondary antibodies in ELISA.
Can't Find What You're Looking For? We can help you source the best match or customize a recombinant protein solution for your study. Options may include species (human/mouse/rat), protein region/domain (full-length vs fragment), tag or label (His/GST/FLAG/biotin/fluorescent), expression system (E. coli/HEK293/insect), purity grade, formulation (buffer, carrier-free, glycerol-free), activity/functional validation (binding or enzymatic assays), endotoxin level (low-endotoxin for cell-based work), mutants/variants (point mutations, isoforms), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
- W. R. Godfrey, et al, (1994) J Exp Med 180: 757-763.
- L.M. Higgins, et al, (1999) J Immunol 162: 486-493.
- A.D. Weinberg, et al, (1999) J Immunol 162: 1818-1826.
- V.Y. Taraban, et al, (2002) Eur J. Immunol. 32: 3617-3627.
- V. Malmstrom, et al, (2001) J Immunol 166: 6972.
- C. Nohara, et al, (2001) J Immunol 166: 2108-2115.
- X. Yuan, et al, (2003) J Immunol 170: 2949-2955.
- L. Tian, et al, (2002) Transplantation 74(1): 133-138.
